ArticleBlood cancer discovery2021
An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities.
Open access · greenAbstract read
In one paragraph
Article in Blood cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 37 citations in OpenAlex.
- MyD88 self-assembles into supramolecular filaments to amplify NF-κB signaling.Fundamental research · 2026Article
- Cancer and aging: complex associations and therapeutic targets.Molecular biomedicine · 2026Review
- Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cells.Cell death & disease · 2026Article
- Redox destabilization by ibrutinib promotes ferroptosis in diffuse large B-cell lymphoma (DLBCL).Cell death discovery · 2025Article
- Lymphoma accelerates T cell and tissue aging.Cancer cell · 2025Article
- EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function.Cancer cell · 2025Article
- Genetic Mouse Models of Lymphomas.Methods in molecular biology (Clifton, N.J.) · 2025Article
- MEF2B C-terminal mutations enhance transcriptional activity and stability to drive B cell lymphomagenesis.Nature communications · 2024Article
- An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphoma.Blood advances · 2024Article
- The Diverse Roles of ETV6 Alterations in B-Lymphoblastic Leukemia and Other Hematopoietic Cancers.Advances in experimental medicine and biology · 2024Review
- Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells.Cell death & disease · 2023Article
- Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.Blood advances · 2023Article
- Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling.International journal of molecular sciences · 2023Article
- An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas.Cancer discovery · 2023Article
- Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies.Blood cancer discovery · 2023Article
- Mouse models of diffuse large B cell lymphoma.Frontiers in immunology · 2023Review
- Article
- Article
- SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis.Cancer discovery · 2022Article
- SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.Blood · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 12 institutions in 3 countries.
Ruth Flümann *University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinic I of Internal Medicine, Cologne, Germany.
Tim Rehkämper *University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinic I of Internal Medicine, Cologne, Germany.
Pascal Nieper *University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinic I of Internal Medicine, Cologne, Germany.
Pauline PfeifferUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Clinic I of Internal Medicine, Cologne, Germany.
Alessandra HolzemUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Clinic I of Internal Medicine, Cologne, Germany.
Sebastian KleinFaculty of Medicine and University Hospital Cologne, Institute of Pathology, University of Cologne, Cologne, Germany.
Sanil BhatiaMedical Faculty, Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Moritz KochanekUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Clinic I of Internal Medicine, Cologne, Germany.
Ilmars KisisUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Clinic I of Internal Medicine, Cologne, Germany.
Benedikt W PelzerUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Clinic I of Internal Medicine, Cologne, Germany.
Heinz AhlertMedical Faculty, Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Julia HauerDepartment of Pediatrics, Pediatric Hematology and Oncology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Alexandra da Palma GuerreiroUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Clinic I of Internal Medicine, Cologne, Germany.
Jeremy A RyanDana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-3327-1283
Maurice ReimannCharité Universitätsmedizin Berlin, Medical Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Virchow Campus, Berlin, Germany.
Arina RiabinskaUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Clinic I of Internal Medicine, Cologne, Germany.
Janica WiedersteinCologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
Marcus KrügerCologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
Martina DeckertCenter for Integrated Oncology, University of Cologne, Cologne, Germany.
Janine AltmüllerCologne Center for Genomics (CCG), University of Cologne, Cologne, Germany.
Andreas R KlattFaculty of Medicine and University Hospital Cologne, Institute of Clinical Chemistry, University of Cologne, Cologne, Germany.
Lukas P FrenzelUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Clinic I of Internal Medicine, Cologne, Germany.
Laura PasqualucciDepartment of Pathology and Cell Biology, Institute for Cancer Genetics and the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York.ORCID 0000-0001-6819-7370
Wendy BéguelinDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, New York.ORCID 0000-0002-4894-9229
Ari M MelnickDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, New York.ORCID 0000-0002-8074-2287
Sandrine SanderAdaptive Immunity and Lymphoma Group, German Cancer Research Center/National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
Manuel Montesinos-RongenCenter for Integrated Oncology, University of Cologne, Cologne, Germany.ORCID 0000-0003-4724-5526
Anna BrunnCenter for Integrated Oncology, University of Cologne, Cologne, Germany.
Philipp LohneisCenter for Integrated Oncology, University of Cologne, Cologne, Germany.
Reinhard BüttnerCenter for Integrated Oncology, University of Cologne, Cologne, Germany.
Hamid KashkarCenter for Molecular Medicine, University of Cologne, Cologne, Germany.ORCID 0000-0003-2796-1429
Arndt BorkhardtMedical Faculty, Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Anthony LetaiDana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Thorsten PersigehlCenter for Integrated Oncology, University of Cologne, Cologne, Germany.
Martin PeiferCenter for Integrated Oncology, University of Cologne, Cologne, Germany.
Clemens A SchmittCharité Universitätsmedizin Berlin, Medical Department of Hematology, Oncology and Tumor Immunology, and Molekulares Krebsforschungszentrum - MKFZ, Virchow Campus, Berlin, Germany.ORCID 0000-0002-4731-2226
Hans Christian Reinhardt *Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University Duisburg-Essen, German Cancer Consortium (DKTK Partner Site Essen), Essen, Germany. christian.reinhardt@uk-essen.de.ORCID 0000-0001-5706-9349
Gero Knittel *University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinic I of Internal Medicine, Cologne, Germany.
University of Cologne · DEHeinrich Heine University Düsseldorf · DECologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases · DECornell University · USDana-Farber Cancer Institute · USUniversity Hospital Cologne · DECancer Genetics (United States) · USDKFZ-ZMBH Alliance · DEEssen University Hospital · DEHeidelberg University · DEJohannes Kepler University of Linz · ATNational Center for Tumor Diseases · DE
Funding
Role of MLL2 Gene Inactivation in B cell Non Hodgkin LymphomaR01CA172492 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PASQUALUCCI, LAURA · 2013 to 2022
$3.6MNCI NIH HHS R01 CA172492
Abstract
Based on gene expression profiles, diffuse large B cell lymphoma (DLBCL) is sub-divided into germinal center B cell-like (GCB) and activated B cell-like (ABC) DLBCL. Two of the most common genomic aberrations in ABC-DLBCL are mutations in
Indexed as
Lymphoma, Large B-Cell, DiffuseMyeloid Differentiation Factor 88AnimalsGenes, bcl-2Germinal CenterMiceProto-Oncogene Proteins c-bcl-2Myd88 protein, mouseMyeloid Differentiation Factor 88Proto-Oncogene Proteins c-bcl-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.